Lantheus Holdings Inc (NASDAQ:LNTH) Stock Is Shorted More

May 31, 2018 - By Adrian Erickson

The stock of Lantheus Holdings Inc (NASDAQ:LNTH) registered an increase of 48.6% in short interest. LNTH’s total short interest was 897,400 shares in May as published by FINRA. Its up 48.6% from 603,900 shares, reported previously. With 284,600 shares average volume, it will take short sellers 3 days to cover their LNTH’s short positions. The short interest to Lantheus Holdings Inc’s float is 2.49%.

The stock decreased 1.41% or $0.2 during the last trading session, reaching $14. About 739,142 shares traded or 77.56% up from the average. Lantheus Holdings, Inc. (NASDAQ:LNTH) has declined 14.41% since May 31, 2017 and is downtrending. It has underperformed by 26.98% the S&P500.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide. The company has market cap of $535.93 million. The Company’s principal products include DEFINITY, an ultrasound contrast imaging agent for use in patients with suboptimal echocardiograms; TechneLite, a self-contained system or generator of technetium used by radiopharmacies to prepare various nuclear imaging agents; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging of cerebral blood flow. It has a 4.42 P/E ratio. The firm also offers injectable technetium-labeled imaging agents, including Cardiolite, used in myocardial perfusion imaging procedures; and Neurolite, which is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke.

Another recent and important Lantheus Holdings, Inc. (NASDAQ:LNTH) news was published by which published an article titled: “Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q1 2018 Results – Earnings Call Transcript” on May 03, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: